{
    "clinical_study": {
        "@rank": "139762", 
        "brief_summary": {
            "textblock": "To assess the safety and tolerance of multiple oral doses of 141W94 alone, in combination\n      with 1592U89, and in combination with Retrovir and Epivir, administered to patients with HIV\n      infection as measured by the development of clinical adverse experiences and laboratory test\n      abnormalities. To determine the steady-state pharmacokinetics of 141W94 alone and in\n      combination with 1592U89 after multiple oral dosing. To obtain preliminary evidence of\n      antiretroviral activity of 141W94 alone and in combination with 1592U89, the antiretroviral\n      effect of combined Retrovir/Epivir and the antiretroviral effect of 141W94 when added to\n      Retrovir/Epivir or to 1592U89/Retrovir/Epivir."
        }, 
        "brief_title": "A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "60 HIV-infected patients will be sequentially assigned to receive 1 of 5 doses of 141W94\n      alone or 141W94 plus 1592U89. After each patient has completed 4 weeks of the assigned\n      regimen (Phase A), the patient will receive Epivir and Retrovir for up to 8 months (Phase\n      B). Patients originally assigned, in Phase A, to receive 141W94 and 1592U89 continue to\n      receive 1592U89 during this period. Upon termination of Phase B, 141W94 is added to existing\n      regimens of Phase B (Phase C). Phase C will last for 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Localized therapy such as intralesional injections for Kaposi's sarcoma.\n\n        Patients must have:\n\n          -  HIV infection documented by a licensed HIV antibody ELISA confirmed by:\n\n          -  Western blot, or positive HIV blood culture, or positive HIV serum antigen and second\n             antibody test positive by a method other than ELISA.\n\n          -  CD4+ counts >= 150 and <= 400 cells/mm3 within 2 weeks of study entry.\n\n             1. Anticipated need for cytotoxic chemotherapeutic agents within 4 weeks prior to\n             entry.\n\n          -  Alprazolam, carbamazepine, codeine, clarithromycin, dapsone, diazepam, diltiazem,\n             erythromycin, estrogens, glucocorticoids, imipramine, itraconazole, ketoconazole,\n             lidocaine, lovastatin, nifedipine, phenobarbital, phenytoin, quinidine, rifabutin,\n             rifampin and warfarin.\n\n          -  The following medications should be used with caution in most instances or not at\n             all:\n\n          -  terfenadine, astemizole, cisapride, triazolam and midazolam.\n\n        Anticipated need for treatment with radiation therapy within 4 weeks prior to entry.\n\n        1. Treatment with cytotoxic chemotherapeutic agents within 4 weeks prior to entry.\n\n          -  Patients who have previously received a protease inhibitor.\n\n          -  Antiretroviral therapy within 2 weeks prior to enrollment.\n\n        NOTE:\n\n          -  Patients with a known intolerance to either retrovir or epivir are not eligible for\n             Phase B of this study.\n\n        NOTE:\n\n          -  Patients with previous epivir (3TC) experience will not be eligible for Regimen 6 of\n             this study (combination therapy with 141W94 and 1592U89).\n\n          -  Treatment with immunomodulating agents, including but not limited to systemic\n             corticosteroids, IL-2, alpha-IFN, beta-IFN, or gamma-IFN within 4 weeks prior to\n             entry.\n\n          -  Treatment with HIV immunotherapeutic vaccine within 3 months prior to entry.\n             Treatment with radiation therapy within 4 weeks prior to entry. Patients with current\n             alcohol or illicit drug use which, in the opinion of the principal investigator, may\n             interfere with the patients' ability to comply with the dosing schedule and protocol\n             evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002183", 
            "org_study_id": "264B"
        }, 
        "intervention": [
            {
                "intervention_name": "Abacavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Zidovudine", 
                "Lamivudine", 
                "Amprenavir", 
                "Abacavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Drug Administration Schedule", 
            "HIV Protease Inhibitors", 
            "VX 478", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "UCSD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "Univ of Colorado Health Sciences Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Schooley R. Preliminary data from a phase I/II study on the safety and antiviral efficacy of the combination of 141W94 plus 1592U89 in HIV-infected patients with 150 to 400 CD4+ cells/mm(3). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:206 (abstract no LB3)"
            }, 
            {
                "PMID": "11120940", 
                "citation": "Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother. 2001 Jan;45(1):30-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002183"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1997"
    }, 
    "geocoordinates": {
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "UCSD": "32.715 -117.157", 
        "Univ of Colorado Health Sciences Ctr": "39.739 -104.985"
    }
}